Tags

Type your tag names separated by a space and hit enter

MAS receptors mediate vasoprotective and atheroprotective effects of candesartan upon the recovery of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality.
Eur J Pharmacol. 2015 Oct 05; 764:173-188.EJ

Abstract

AT1 antagonists effectively prevent atherosclerosis since AT1 upregulation and angiotensin II-induced proinflammatory actions are critical to atherogenesis. Despite the classic mechanisms underlying the vasoprotective and atheroprotective actions of AT1 antagonists, the cross-talk between angiotensin-converting enzyme-angiotensin II-AT1 and angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axes suggests other mechanisms beyond AT1 blockage in such effects. For instance, angiotensin-converting enzyme 2 activity is inhibited by reactive oxygen species derived from AT1-mediated proinflammatory signaling. Since angiotensin-(1-7) promotes antiatherogenic effects, we hypothesized that the vasoprotective and atheroprotective effects of AT1 antagonists could result from their inhibitory effects on the AT1-mediated negative modulation of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality. Interestingly, our results showed that early atherosclerosis triggered in thoracic aorta from high cholesterol fed-Apolipoprotein E-deficient mice impairs angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality by a proinflammatory-redox AT1-mediated pathway. In such mechanism, AT1 activation leads to the aortic release of tumor necrosis factor-α, which stimulates NAD(P)H oxidase/Nox1-driven generation of superoxide and hydrogen peroxide. While hydrogen peroxide inhibits angiotensin-converting enzyme 2 activity, superoxide impairs MAS functionality. Candesartan treatment restored the functionality of angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis by inhibiting the proinflammatory-redox AT1-mediated mechanism. Candesartan also promoted vasoprotective and atheroprotective effects that were mediated by MAS since A779 (MAS antagonist) co-treatment inhibited them. The role of MAS receptors as the final mediators of the vasoprotective and atheroprotective effects of candesartan was supported by the vascular actions of angiotensin-(1-7) upon the recovery of the functionality of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis.

Authors+Show Affiliations

Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences from Ribeirão Preto (FCFRP), University of São Paulo (USP), Ribeirão Preto, SP, Brazil. Electronic address: l.pernomian@usp.br.Department of Pharmacology, Faculty of Medicine from Ribeirão Preto (FMRP), USP, Ribeirão Preto, SP, Brazil.Department of Physics and Chemistry, FCFRP, USP, Ribeirão Preto, SP, Brazil.Department of Pharmacology, Faculty of Medicine from Ribeirão Preto (FMRP), USP, Ribeirão Preto, SP, Brazil.Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences from Ribeirão Preto (FCFRP), University of São Paulo (USP), Ribeirão Preto, SP, Brazil.Department of Morphology, Faculty of Odontology from Ribeirão Preto (FORP), USP, Ribeirão Preto, SP, Brazil.Department of Physics and Chemistry, FCFRP, USP, Ribeirão Preto, SP, Brazil.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26144375

Citation

Pernomian, Larissa, et al. "MAS Receptors Mediate Vasoprotective and Atheroprotective Effects of Candesartan Upon the Recovery of Vascular Angiotensin-converting Enzyme 2-angiotensin-(1-7)-MAS Axis Functionality." European Journal of Pharmacology, vol. 764, 2015, pp. 173-188.
Pernomian L, do Prado AF, Gomes MS, et al. MAS receptors mediate vasoprotective and atheroprotective effects of candesartan upon the recovery of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality. Eur J Pharmacol. 2015;764:173-188.
Pernomian, L., do Prado, A. F., Gomes, M. S., Pernomian, L., da Silva, C. H. T. P., Gerlach, R. F., & de Oliveira, A. M. (2015). MAS receptors mediate vasoprotective and atheroprotective effects of candesartan upon the recovery of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality. European Journal of Pharmacology, 764, 173-188. https://doi.org/10.1016/j.ejphar.2015.07.007
Pernomian L, et al. MAS Receptors Mediate Vasoprotective and Atheroprotective Effects of Candesartan Upon the Recovery of Vascular Angiotensin-converting Enzyme 2-angiotensin-(1-7)-MAS Axis Functionality. Eur J Pharmacol. 2015 Oct 5;764:173-188. PubMed PMID: 26144375.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MAS receptors mediate vasoprotective and atheroprotective effects of candesartan upon the recovery of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality. AU - Pernomian,Larissa, AU - do Prado,Alejandro F, AU - Gomes,Mayara S, AU - Pernomian,Laena, AU - da Silva,Carlos H T P, AU - Gerlach,Raquel F, AU - de Oliveira,Ana M, Y1 - 2015/07/02/ PY - 2015/04/06/received PY - 2015/06/30/revised PY - 2015/07/01/accepted PY - 2015/7/7/entrez PY - 2015/7/7/pubmed PY - 2016/7/29/medline KW - AT(1) receptors KW - Angiotensin-(1-7) KW - Angiotensin-converting-enzyme 2 KW - Candesartan KW - Early atherosclerosis KW - MAS receptors SP - 173 EP - 188 JF - European journal of pharmacology JO - Eur. J. Pharmacol. VL - 764 N2 - AT1 antagonists effectively prevent atherosclerosis since AT1 upregulation and angiotensin II-induced proinflammatory actions are critical to atherogenesis. Despite the classic mechanisms underlying the vasoprotective and atheroprotective actions of AT1 antagonists, the cross-talk between angiotensin-converting enzyme-angiotensin II-AT1 and angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axes suggests other mechanisms beyond AT1 blockage in such effects. For instance, angiotensin-converting enzyme 2 activity is inhibited by reactive oxygen species derived from AT1-mediated proinflammatory signaling. Since angiotensin-(1-7) promotes antiatherogenic effects, we hypothesized that the vasoprotective and atheroprotective effects of AT1 antagonists could result from their inhibitory effects on the AT1-mediated negative modulation of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality. Interestingly, our results showed that early atherosclerosis triggered in thoracic aorta from high cholesterol fed-Apolipoprotein E-deficient mice impairs angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality by a proinflammatory-redox AT1-mediated pathway. In such mechanism, AT1 activation leads to the aortic release of tumor necrosis factor-α, which stimulates NAD(P)H oxidase/Nox1-driven generation of superoxide and hydrogen peroxide. While hydrogen peroxide inhibits angiotensin-converting enzyme 2 activity, superoxide impairs MAS functionality. Candesartan treatment restored the functionality of angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis by inhibiting the proinflammatory-redox AT1-mediated mechanism. Candesartan also promoted vasoprotective and atheroprotective effects that were mediated by MAS since A779 (MAS antagonist) co-treatment inhibited them. The role of MAS receptors as the final mediators of the vasoprotective and atheroprotective effects of candesartan was supported by the vascular actions of angiotensin-(1-7) upon the recovery of the functionality of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis. SN - 1879-0712 UR - https://www.unboundmedicine.com/medline/citation/26144375/MAS_receptors_mediate_vasoprotective_and_atheroprotective_effects_of_candesartan_upon_the_recovery_of_vascular_angiotensin_converting_enzyme_2_angiotensin__1_7__MAS_axis_functionality_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(15)30135-7 DB - PRIME DP - Unbound Medicine ER -